Stka.Ns

The company maintains a strong liquidity position, with a current ratio of 5.33, indicating that it has more than five times the current assets to cover its current liabilities. Its cash and equivalents amount to INR 254.85 million, which is a significant portion of its total assets of INR 637.39 million. The debt-to-equity ratio is 0.11, suggesting a conservative capital structure with minimal reliance on debt financing.

In terms of profitability, STKA.NS reports a return on equity (ROE) of 19.06% and a return on assets (ROA) of 15.4%, both of which are strong indicators of efficient use of equity and assets to generate profit. The company's net income of INR 98.15 million is derived from a gross profit of INR 1.54 billion, reflecting a healthy margin structure. These metrics are well above the typical thresholds for the pharmaceutical industry, suggesting a robust performance relative to its peers.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of geographic segmentation may indicate a concentration risk, as the company's performance is tied to a specific market or region. However, the absence of detailed geographic breakdowns in the input data limits further analysis on this front.

Looking at the growth trajectory, the company's operating cash flow is negative at INR -50.70 million, which may signal reinvestment in operations or expansion. However, the free cash flow is positive at INR 59.32 million, indicating that the company is generating sufficient cash to support operations and potentially fund growth initiatives. The capital expenditure of INR -51.84 million suggests ongoing investment in infrastructure or production capabilities, which could support future revenue growth.

The risk assessment indicates a low level of liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt-to-equity ratio and strong cash reserves further support this assessment. There is no evidence of dilution potential in the basic shares outstanding, as the diluted shares are equal to the basic shares. This suggests that the company has not issued any dilutive securities that could reduce the ownership percentage of existing shareholders.

Recent events, as reflected in the financial data, show a consistent revenue stream and a strong gross profit margin. The company's operating income of INR 129.28 million and net income of INR 98.15 million indicate a stable and profitable business model. However, the negative operating cash flow may warrant further investigation to understand the underlying causes and their potential impact on future performance.